英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
---|---|---|---|---|---|---|
Palbociclib (PD0332991) Isethionate
|
827022-33-3 |
PD0332991 ISETHIONATE
|
羟乙烷磺酸帕布昔利布;帕博西丽;PALBOCICLIB 羟乙基磺酸盐;帕波克利;帕布西利布羟基乙磺酸盐;帕布昔利布羟乙基磺酸盐;羟乙基磺酸帕博西丽;CS-1265
|
C26H35N7O6S |
573.6644 | 804-556-2 |
P505-15
|
1370261-96-3 |
2-[[(1R,2S)-2-氨基环己基]氨基]-4-[[3-(2H-1,2,3-三唑-2-基)苯基]氨基]-5-嘧啶甲酰胺
|
2-[[(1R,2S)-2-氨基环己基]氨基]-4-[[3-(2H-1,2,3-三唑-2-基)苯基]氨基]-5-嘧啶甲酰胺;PRT062607;P505-15;BIIB-057
|
C19H23N9O |
393.44562 | |
OSU-03012
|
742112-33-0 |
2-氨基-N-[4-[5-(2-菲基)-3-(三氟甲基)-1H-吡唑-1-基]苯基]乙酰胺
|
N;AAR-12;OSU03012;OSU 03012;CS-1848;2-氨基-N-[4-[5-(2-菲基)-3-(三氟甲基)-1H-吡唑-1-基]苯基]乙酰胺;OSU-03012 (AR-12);N;AAR-12;OSU03012;OSU 03012
|
C26H19F3N4O |
460.46 | |
BKM120 (NVP-BKM120)
|
944396-07-0 |
BKM120 (NVP-BKM120, Buparlisib)
|
5-[2,6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺;NVP-BKM-120(5-[2,6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺);BKM120 (NVP-BKM120,)5-[2,6-二(4-吗啉基)-4-嘧啶基]-4-(三氟甲基)-2-吡啶胺;5-(2,6-二吗啉嘧啶-4-基)-4-(三氟甲基)吡啶-2-胺;NVP-BKM-120;BKM-120;BUPARLISIB;BKM120;BKM 120
|
C18H21F3N6O2 |
410.39355 | |
NVP-BGT226
|
1245537-68-1 |
1-(3-三氟甲基-4-(哌嗪-1-基)苯基)-8-(6-甲氧基吡啶-3-基)-3-甲基-1H-咪唑并[4,5-C]喹啉-2(3H)-酮马来酸盐
|
BGT-226;NVP BGT226 (BGT226);CS-382;BGT226 (NVP-BGT226);NVP-BGT226;1-(3-三氟甲基-4-(哌嗪-1-基)苯基)-8-(6-甲氧基吡啶-3-基)-3-甲基-1H-咪唑并[4,5-C]喹啉-2(3H(-酮马来酸盐
|
C28H25F3N6O2.C4H4O4 |
650.60447 | |
AUY922 (NVP-AUY922)
|
747412-49-3 |
5-[2,4-二羟基-5-异丙基苯基]-N-乙基-4-[4-(4-吗啉基甲基)苯基]-3-异恶唑甲酰胺
|
AUY922,NVP-AUY-922,LUMINESPIB;5-(2,4-二羟基-5-异丙基苯基)-N-乙基-4-(4-(吗啉代甲基)苯基)异恶唑-3-甲酰胺;5-[2,4-二羟基-5-异丙基苯基]-N-乙基-4-[4-(4-吗啉基甲基)苯基]-3-异恶唑甲酰胺;信号通路抑制剂(NVP-AUY922);CS-209;AUY 922;AUY-922;NVP-AUY922;NVP-AUY922-NX;AUY922;VER-52296;LUMINESPIB;NVP-AUY922;VER-52296;NVP-AUY 922;AUY-922;VER 52296;VER52296
|
C26H31N3O5 |
465.547 | |
Nutlin-3b
|
675576-97-3 |
4-[[(4R,5S)-4,5-双(4-氯苯基)-4,5-二氢-2-[4-甲氧基-2-(1-甲基乙氧基)苯基]-1H-咪唑-1-基]羰基]-2-哌嗪酮
|
4-[[(4R,5S)-4,5-双(4-氯苯基)-4,5-二氢-2-[4-甲氧基-2-(1-甲基乙氧基)苯基]-1H-咪唑-1-基]羰基]-2-哌嗪酮;NUTLIN-3B;NUTLIN 3B;(+)-NUTLIN-3;NUTLIN 3B
|
C30H30Cl2N4O4 |
581.4896 | |
4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-Piperazinone
|
675576-98-4 |
4-[[(4S,5R)-4,5-双(4-氯苯基)-4,5-二氢-2-[4-甲氧基-2-(1-甲基乙氧基)苯基]-1H-咪唑-1-YL]羰基]-2-哌嗪酮
|
CS-391;4-[[(4S,5R)-4,5-双(4-氯苯基)-4,5-二氢-2-[4-甲氧基-2-(1-甲基乙氧基)苯基]-1H-咪唑-1-YL]羰基]-2-哌嗪酮;4-[[(4S,5-二氢-2-[4-甲氧基-2-(1-甲基乙氧基)苯基]-1H-咪唑-1-基]羰基]-2-哌嗪酮
|
C30H30Cl2N4O4 |
581.497 | |
Nutlin-3
|
548472-68-0 |
REL-4-[[(4R,5S)-4,5-双(4-氯苯基)-4,5-二氢-2-[4-甲氧基-2-(1-甲基乙氧基)苯基]-1H-咪唑-1-基]羰基]-2-哌嗪酮
|
NUTLIN3;NUTLIN 3;CS-390;REL-4-[[(4R,5S)-4,5-双(4-氯苯基)-4,5-二氢-2-[4-甲氧基-2-(1-甲基乙氧基)苯基]-1H-咪唑-1-基]羰基]-2-哌嗪酮;4-[4,5-双(4-氯苯基)-2-(4-甲氧基-2-异丙氧基苯基)-4,5-二氢咪唑-1-羰基]哌嗪-2-酮;()-NUTLIN-3
|
C30H30Cl2N4O4 |
581.49 | 200-258-5 |
KU57788(NU7441)
|
503468-95-9 |
8-(4-二苯并噻吩基)-2-(4-吗啉基)-4H-1-苯并吡喃-4-酮
|
NU7441;KU57788;NU 7441 (KU 57788);8-(4-二苯并噻吩基)-2-(4-吗啉基)-4H-1-苯并吡喃-4-酮 KU57788(NU7441);CS-181;8-(4-二苯并噻吩基)-2-(4-吗啉基)-4H-1-苯并吡喃-4-酮;NU7441 (KU-57788);KU 57788;NU-7441
|
C25H19NO3S |
413.48826 | |
b-AP15
|
1009817-63-3 |
(3E,5E)-3,5-二[(4-硝基苯基)亚甲基]-1-(1-氧代-2-丙烯-1-基)-4-哌啶酮
|
(3E,5E)-3,5-二[(4-硝基苯基)亚甲基]-1-(1-氧代-2-丙烯-1-基)-4-哌啶酮
|
C22H17N3O6 |
419.38688 | |
1 NM-PP1
|
221244-14-0 |
4-氨基1-叔丁基-3-(1'-萘甲基)吡唑并[3,4-D]嘧啶
|
4-氨基1-叔丁基-3-(1'-萘甲基)吡唑并[3,4-D]嘧啶;CS-920
|
C20H21N5 |
331.41 | |
MK-4827
|
1038915-60-4 |
尼拉帕尼
|
MK 4827;MK-4827;MK4827;-[4-((3S)-3-哌啶基)苯基]-2H-吲唑-7-甲酰胺;(S)-2-(4-(哌啶-3-基)苯基)-2H-吲唑-7-羧酰胺;尼拉帕布;尼拉帕尼(碱);(S)-2-((哌啶-3-基)苯基)-吲唑-7-甲酰胺;2-[4-((3S)-3-哌啶基)苯基]-2H-吲唑-7-甲酰胺;尼拉帕尼
|
C19H20N4O |
320.3883 | |
Nintedanib
|
656247-17-5 |
尼达尼布
|
尼达尼布标准品016;BIBF1120;VARGATEF;BIBF-1120;尼达尼布杂质(A-D);尼达尼布乙烷磺酸盐;尼达尼布杂质对照品;(3Z)-2,3-二氢-3-[[[4-[甲基[2-(4-甲基-1-哌嗪基)乙酰]氨基]苯基]氨基]苯亚甲基]-2-氧代-1H-吲哚-6-甲酸甲酯;尼达尼布杂质系列;NINTEDANIB;BIBF1120;VARGATEF;BIBF-1120
|
C31H33N5O4 |
539.62482 | 1592732-453-0 |
Nilotinib
|
641571-10-0 |
尼罗替尼
|
TASIGNA;AMN-107;AMN107;尼罗替尼及其中间体;4-甲基-3-((4-(3-吡啶基)-2-嘧啶基)氨基)-N-(5-(4-甲基-1H-咪唑-1-基)-3-(三氟甲基)苯基)苯甲酰;TASIGNA NILOTINIB;NILO锡IB;苯甲酰胺,4-甲基-N-[3-(4-甲基-1H-咪唑-1-基)-5-(三氟甲基)苯基]-3-[[4-(3-吡啶基)-2-嘧啶基]氨基]-;AMN107;TASIGNA;尼洛替尼 D7
|
C28H22F3N7O |
529.52 | 700-544-5 |
MS-275 (Entinostat)
|
209783-80-2 |
恩替诺特
|
MS275;MS 275;CS-189;恩替诺特ENTINOSTAT;N-[[4-[[(2-氨基苯基)氨基]甲酰]苯基]甲基]氨基甲酸 3-吡啶基甲基酯;恩替诺特;MS275;SNDX 275
|
C21H20N4O3 |
376.4085 | |
Mps1-IN-2
|
1228817-38-6 |
9-环戊基-2-[[2-乙氧基-4-(4-羟基哌啶-1-基)苯基]氨基]-5-甲基-8,9-二氢-5H-嘧啶并[4,5-B][1,4]二氮杂卓-6(7H)-酮
|
9-Cyclopentyl-2-[[2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenyl]amino]-5-methyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one Mps1-in-2;Mps1-IN-2;Msp1-IN-2;9-Cyclopentyl-2-[[2-ethoxy-4-(4-hydroxypiperidin-1-yl)phenyl]amino]-5-methyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one
|
|||
MGCD0103 (Mocetinostat)
|
726169-73-9 |
N-(2-氨基苯基)-4-([[4-(吡啶-3-基)嘧啶-2-基]氨基]甲基)苯甲酰胺
|
CS-1929;MGCD0103;MGCD 0103;MGCD-0103;MG0103;MGCD0103;MGCD 0103;MGCD-0103;N-(2-氨基苯基)-4-([[4-(吡啶-3-基)嘧啶-2-基]氨基]甲基)苯甲酰胺
|
C23H20N6O |
396.452 | |
MLN9708
|
1201902-80-8 |
MLN9708
|
枸橼酸艾沙佐米;埃沙佐米柠檬酸盐4-羧基-2-[(1R)-1-[[2-[(2,5-二氯苯甲酰基)氨基]乙酰基]氨基]-3-甲基丁基]-6-氧代-1,3,2-二氧硼杂环己-4-乙酸;CS-1830;艾沙唑咪;MLN9708;MLN-9708;埃沙左米柠檬酸;艾沙佐米柠檬酸盐;MLN9708,20S蛋白酶体抑制剂
|
C20H23BCl2N2O9 |
517.12162 | |
MLN4924
|
905579-51-3 |
氨基磺酸 [(1S,2S,4R)-4-[4-[[(1S)-2,3-二氢-1H-茚-1-基]氨基]-7H-吡咯并[2,3-D]嘧啶-7-基]-2-羟基环戊基]甲基酯
|
氨基磺酸 [(1S,2S,4R)-4-[4-[[(1S)-2,3-二氢-1H-茚-1-基]氨基]-7H-吡咯并[2,3-D]嘧啶-7-基]-2-羟基环戊基]甲基酯;CS-821;PEVONEDISTAT;MLN-4924
|
C21H25N5O4S |
443.5193 |